CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 115 target
Drug / intervention
Antifungal drug. VORICONAZOL. (VFEND®)drug
Likely dose
Antifungal drug. VORICONAZOL. (VFEND®) 6 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00386802
NCT00386802Phase 4Completed
CompareCT.gov

ANTIVORIFUNGOL:Strategy of Antifungal Use in Oncohematological Neutropenic Patients. Use of Voriconazole as Early Treatment.

PETHEMA Foundation·interventional·Posted Oct 12, 2006·Updated Sep 18, 2009

In Brief

A Phase 4 clinical trial evaluating Antifungal drug. VORICONAZOL. (VFEND®) for Invader Fungal Infection. Completed, enrolled 115 participants across 13 sites.

Detailed Summary

Primary purpose: Frequency of use of broad-spectrum antifungals in the episode of neutropenia. Secondary purposes:To determine the safety and toxicity measure by: 1. Frequency of Invader Fungal Infection. 2. Frequency of global use of broad-spectrum antifungals as amphotericine, itraconazole, voriconazole, caspofungin, terbinafine, during the period of study. 3. Mortality 4. Development of nephrotoxicity 5. Use of galactomannan in this clinical context 6. Time of administration of empirical antifungal therapy of broad-spectrum.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInvader Fungal Infection
CountriesSpain
Collaborators--

Timeline

Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 12, 2006
Enrollment StartAug 1, 2006
Primary CompletionDec 1, 2008
Study CompletionJan 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 19.7 years ago

Interventions

Antifungal drug. VORICONAZOL. (VFEND®)drug

I.V charge dose 6 mg/kg/12h (2 doses) Maintenance iv treatment 4 mg/kg/12h during 6 days, followed by oral treatment (200 mg/12h)